Skip to content
To the full analysis

Silence Therapeutics stock: balance sheet and debt

SLN
$19.80Closing price of 12 Nov 2026MEQIRI Score 45 out of 100

Silence Therapeutics has a debt to equity ratio of 0.

Daily figure as of 13 Nov 2026

Debt / Equity
0
Interest coverage
no data
Current ratio
8.72
Cash & equivalents
$85.11M
Total assets
$131.44M
Equity ratio
47.4%
Goodwill
$10.62M
Plus intangible assets of $288K
Net debt
−$84.95M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Silence Therapeutics plc is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$16.75M$6.97M$6.24M93.8%−$8.82M
2007$19.48M$7.43M$6.65M90.7%−$10.17M
2008$14.38M$9.42M$8.61M93.5%−$3.35M
2009$10.99M$8.87M$8.13M80.9%−$1.13M
2010$33.96M$29.29M$28.35M95.0%−$3.57M
2011$33.44M$29.31M$28.34M96.2%−$3.69M
2012$17.08M$7.86M$7.33M94.4%−$8.91M
2013$29.3M$7.8M$7.55M94.1%−$20.89M
2014$29.77M$7.08M$7.08M93.2%−$21.86M
2015$61.55M$6.67M$6.66M98.2%−$51.91M
2016$55.79M$7.75M$7.71M97.1%−$39.01M
2017$55.01M$8.06M$8.03M95.2%−$43.06M
2018$38.89M$8.19M$8.13M90.2%−$26.54M
2019$46.08M$7.73M$7.69M45.4%−$33.23M
2020$85.97M$8.14M$8.13M10.5%−$37.11M
2021$96.19M$7.62M$7.59M8.9%−$73.4M
2022$107.5M$8.33M$8.01M20.5%−$70.7M
2023$94.53M$10.34M$9.98M23.3%−$54.16M
2024$161.85M$7.75M$7.5M66.1%−$117.59M
2025$131.44M$10.91M$10.62M47.4%−$84.95M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$8.82M$15.71M$00
2007$10.17M$17.68M$00
2008$3.35M$13.44M$00
2009$1.13M$8.89M$00
2010$3.57M$32.27M$00
2011$3.69M$32.18M$00
2012$8.91M$16.12M$00
2013$20.89M$27.58M$00
2014$21.86M$27.76M$00
2015$51.91M$60.43M$00
2016$39.01M$54.18M$00
2017$43.06M$52.35M$00
2018$26.54M$35.06M$00
2019$33.52M$20.91M$287K0.01
2020$37.45M$9.06M$341K0.04
2021$73.54M$8.53M$137K0.02
2022$71.14M$22.07M$446K0.02
2023$54.44M$21.99M$273.81K0.01
2024$117.68M$107.05M$93.45K0
2025$85.11M$62.3M$160K0

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy